Hassan Hamade, MD, of the Icahn School of Medicine at Mount Sinai, spoke about some of the most notable takeaways on deucravacitinib for psoriasis from the expert consensus panel in which he took part—the findings of which were published in the Journal of Drugs in Dermatology.1
In his previous HCPLive interview, Hamade discussed the clinical recommendations related to the use of deucravacitinib in psoriasis management.2 He also highlighted his views on deucravacitinib and experiences managing inflammatory skin conditions. In this segment of his interview, Hamade was asked whether the group’s findings changed his approach to shared decision-making.
“[In] people who are afraid of needles…you could argue that eventually they’ll get over it, which I’ve seen maybe 5600 times,” Hamade said. “There are patients, however, who’ve reached a point where their psoriatic arthritis has reached debilitation of their joints and of their hands…For those patients, I want to be able to [say], ‘I can give you an injection unless you have somebody at home to do it for you.’ This will be quite hard, so I’d rather give you a pill that I know will benefit you.”
In terms of safety, tolerability, or long-term data, Hamade was asked if anything at the forum increased his confidence or raised new questions about implementing deucravacitinib.
“It was very it was actually awesome that they re-emphasized the longer-term safety data that’s been coming out, which was not unexpected, but always good to see with these oral ‘JAKS’, it’s very good to see,” Hamade said. “I think for dermatologists in particular, more so than rheumatologists or primary care, safety tests are huge, because we have so many options, especially topical options, that are effective enough and safe biologics. So re-emphasizing that was awesome…Things like CPK elevations that weren’t necessarily clinically significant and the consistent yet low rate of thromboembolic events, which makes us comfortable prescribing these things.”
For any further information on deucravacitinib and its utilization in patients with inflammatory conditions such as psoriasis, view Hamade’s full vide segment posted above.
The quotes contained in this summary were edited for the purposes of clarity.
References
-
Shah M, Burshtein J, Lebwohl M, et al. A Review of the Safety and Efficacy of Deucravacitinib for Plaque Psoriasis: An Expert Consensus Panel. J Drugs Dermatol. 2025 Feb 1;24(2):147-155. doi: 10.36849/JDD.8616. PMID: 39913225.
-
Hamade H. Insights on Deucravacitinib for Psoriasis During Expert Consensus Panel, with Hassan Hamade, MD. HCPLive. July 17, 2025. https://www.hcplive.com/view/insights-deucravacitinib-psoriasis-during-expert-consensus-panel-hassan-hamade-md.